Skip to main content Skip to search Skip to main navigation
News: Europe

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.

According to EFPIA, the number of reported inspections decreased by approximately 25% compared with the 2015–2019 period. The industry interprets this as a possible indication that authorities are increasingly relying on inspections performed by other inspectorates and reducing duplication.

The survey particularly highlights that:

  • foreign inspections are decreasing overall,
  • reliance approaches among PIC/S authorities are advancing,
  • on-site inspections remain the standard,
  • remote inspections are only a backup option,
  • document-only inspections are declining significantly,
  • inspections are becoming more risk-based and system-focused.

EFPIA also reports that implementation of the revised Annex 1 has not led to an increase in inspections at sterile manufacturing sites. In addition, announced and unannounced inspections reportedly showed similar outcomes.

Further trends identified in the survey include:

  • stronger inter-agency coordination,
  • coordinated or joint inspections,
  • harmonised inspection report formats,
  • and digital collaboration platforms for information exchange between authorities.

EFPIA calls on authorities to make broader use of existing reliance tools, particularly PIC/S mechanisms and Mutual Recognition Agreements (MRAs), and to further pursue the vision of “one inspection per site”.


Source:

EFPIA: Annual Regulatory GMP/GDP Inspection Survey 2025 data

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next